Sooraj M.

ICMR-JRF

  • MSc (Area): Biotechnology
  • soorajmathukkada@gmail.com

I have completed MSc in Biotechnology (Amrita Vishwa Vidyapeetham deemed to be University) and BSc in Biotechnology, Chemistry, and Botany (St. Aloysius College-Autonomous, Mangalore). During masters, I worked on a project titled “Expression of HSP70 in Glioma cells Under Photodynamic or Radiofrequency Stress” at Amrita Centre for Nanosciences and Molecular Medicines, Kochi, Kerala. After completion of masters, I worked on several projects at various laboratories in India. I joined Yenepoya Research Centre in January 2020, currently working on a project titled “A novel therapeutic approach to treat myeloid malignancies by manipulation of c-MPL splicing”. I am experienced in molecular techniques such as immunological assays, immunohistochemistry, RT-PCR, multicolor flowcytometry and data analysis.

Experience

  • Junior Research Fellow on a project titled “To evaluate Role of Gamma-Delta T cells in Colorectal Cancer” Tumor immunology laboratory, ACTREC-TMC, Navi Mumbai, Maharashtra, India
  • Project Assistant-II on a project titled “Novel adjuvants for malaria vaccine” under CSIR-IICT, Hyderabad, Telangana, India.

Research Interest/ Area

Cancer Biology, Molecular Biology, Tumor Immunology and Tumor microenvironment

Research

Thrombopoietin (THPO) and its receptor c-MPL are known for their role in regulating hematopoiesis. Two alternate splice forms of c-MPL, MPL-TR and MPL-FL ratio is a critical factor in regulating THPO mediated signaling and hematopoiesis. In diseases such as Acute Myeloid Leukemia (AML), the leukemic cells express high level of c-MPL, which supports enhanced proliferation and survival. Currently, we are trying to characterize the expression of c-MPL and its isoforms in various AML cell lines and to understand the molecular mechanisms underlining the survival of AML cells. Further, developing an antisense oligonucleotide (ASO) mediated approach to alter the c-MPL splice variants as a therapeutic approach for AML.